Synergistic Induction of Tissue Factor by Coagulation Factor Xa and TNF: Evidence for Involvement of Negative Regulatory Signaling Cascades
Enzymes of the blood coagulation pathway enhance the inflammatory response leading to endothelial dysfunction, accounting, in part, for the vascular complications occurring in sepsis and cardiovascular disease. The responses of endothelial cell activation include induction of the expression of tissu...
Saved in:
Published in: | Proceedings of the National Academy of Sciences - PNAS Vol. 102; no. 34; pp. 12077 - 12082 |
---|---|
Main Authors: | , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
National Academy of Sciences
23-08-2005
National Acad Sciences |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Enzymes of the blood coagulation pathway enhance the inflammatory response leading to endothelial dysfunction, accounting, in part, for the vascular complications occurring in sepsis and cardiovascular disease. The responses of endothelial cell activation include induction of the expression of tissue factor (TF), a membrane glycoprotein that promotes thrombosis, and of E-selectin, a cell adhesion molecule that promotes inflammation. In this report, we demonstrate synergistic interactions between the coagulation factor Xa (fXa) and the proinflammatory cytokines TNF, IL-1β, and CD40L, leading to enhanced expression of TF and E-selectin in endothelial cells. A detailed analysis of the molecular pathways that could account for this activity of fXa showed that fXa inhibited the cytokine-induced expression of dual specificity phosphatases, MAP kinase phosphatase-L, -4, -5, and -7, blocking a negative regulatory effect on c-Jun N-terminal kinase. The synergistic interaction between fXa and TNF was also involved in the inhibition of A20 and IκBα expression in the IκB kinase-NF-κB pathway. The data indicate that inhibition of negative regulatory signaling accounts for the amplification of cytokine-induced endothelial cell activation by fXa. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Present address: Portola Pharmaceuticals, South San Francisco, CA 94080. Present address: Medtronic Vascular, Santa Rosa, CA 95403. Communicated by David V. Goeddel, Amgen, Inc., South San Francisco, CA, June 15, 2005 Author contributions: A.H.-Y. and U.S. designed research; A.H.-Y., P.W.W., N.B.-L., L.G.K., K.S.S.P., and D.R.P. performed research; A.H.-Y., P.W.W., L.G.K., K.S.S.P., and U.S. analyzed data; and A.H.-Y., D.R.P., and U.S. wrote the paper. Present address: Quidel Corporation, Santa Clara, CA 95051. To whom correspondence should be addressed. E-mail: usinha@portola.com. Present address: Gladstone Institute of Neurological Disease, San Francisco, CA 94110. Present address: Corgentech, South San Francisco, CA 94080. Abbreviations: TF, tissue factor; fXa, factor Xa; PAR, protease-activated receptor; MAPK, mitogen-activated protein kinase; JNK, c-Jun N-terminal kinase; HUVEC, human umbilical vein endothelial cells. |
ISSN: | 0027-8424 1091-6490 |
DOI: | 10.1073/pnas.0504526102 |